

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

POSITIVE PROFIT ALERT

This announcement is published by Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to the Inside Information Provisions under of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The board of directors of the Company (the “**Board**”) hereby informs the shareholders of the Company (“**Shareholders**”) and potential investors of the Company that, based on the information currently available to the Group and its preliminary assessment of the unaudited consolidated management accounts of the Group for the three months ending 31 March 2021 (the “**Reporting Period**”), it is expected that the Group’s net profit will turn around during the Reporting Period as compared to the corresponding period in 2020. The Group is expected to record an unaudited net profit attributable to shareholders of the listed Company of approximately RMB80,000,000 to RMB100,000,000 during the Reporting Period (corresponding period in 2020: an unaudited net loss attributable to shareholders of the listed Company of RMB24,855,428.82). The unaudited net profit attributable to shareholders of the listed Company after deducting the non-recurring profit or loss is expected to be approximately RMB75,000,000 to RMB95,000,000 (corresponding period in 2020: unaudited net loss attributable to shareholders of the listed Company after deducting the non-recurring profit or loss of RMB35,711,082.59).

As far as the Board is aware, the profit growth with a turn around for the Reporting Period as compared to the corresponding period in 2020 was mainly due to the higher growth in sales revenue of the Group during the Reporting Period as a result of the recovery to normal production and life in society as the novel coronavirus epidemic gradually came under control, as well as the maintaining of the market share of the Group’s products with higher and enhanced market recognition of its products, especially the new products, as the Group continuously and actively launched various market and marketing activities.

The Board hereby reminds the Shareholders and potential investors of the Company that the information set out in this announcement is based on an assessment with reference to the information currently available to the Group and has not been reviewed by the audit committee of the Company and the independent auditors. The Group is still finalizing the unaudited results for the three months ended 31 March 2021 (the “**First Quarterly Report**”), which are subject to adjustments (if necessary). The First Quarterly Report may differ from the data set out in this announcement. Shareholders and potential investors of the Company are advised to read carefully the details of the Group’s First Quarterly Report, which is expected to be published in late April 2021.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC, 26 March 2021

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Ms. Li Yingqi, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.

* *For identification purpose only*